This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction (SOFTNES)

This study has been terminated.
(Study was early terminated due to problems enrolling adequate number of patients)
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: August 26, 2010
Last updated: August 22, 2012
Last verified: August 2012
This is a comparative trial between oxytocin alone and dinoprostone for cervical ripening in unfavorable cervix pregnant women with 38 or more weeks of gestational age.

Condition Intervention Phase
Vaginal Delivery Cesarean Section Drug: Dinoprostone Drug: Oxytocin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase IV, Multicenter, Open Label, Randomized Trial to Compare the Effectiveness and Safety of the Dinoprostone Vaginal Pessary vs. Oxytocin for Women Requiring Cervical Ripening Prior to Induction of Labor

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Vaginal birth delivery within 24 hours and C-section rate [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Treatment failure rate [ Time Frame: 24 hours ]
  • Uterine hyperstimulation and/or fetal distress [ Time Frame: 24 hours ]
  • Use of additional oxytocin [ Time Frame: 24 hours ]

Enrollment: 170
Study Start Date: June 2010
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: Dinoprostone
Active Comparator: B Drug: Oxytocin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Singleton pregnancy
  • Gestational age ≥ 38 weeks
  • Fetal cephalic presentation
  • Bishop score < 6

Exclusion Criteria:

  • No uterine scar (no previous delivery by caesarean section)
  • No more than 3 previous vaginal births
  • No condition that disallows use of prostaglandins for induction of labor
  • Premature rupture of the membranes
  • Oligohydramnios
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01190163

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirão Preto, São Paulo, Brazil
Hospital Municipal Universitário - Faculdade de Medicina do ABC
São Bernardo, São Paulo, Brazil
Hospital M Boi Mirim
São Paulo, Brazil
Hospital Maternidade Leonor Mendes de Barros
São Paulo, Brazil
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01190163     History of Changes
Other Study ID Numbers: FE999901 CS01
Study First Received: August 26, 2010
Last Updated: August 22, 2012

Keywords provided by Ferring Pharmaceuticals:
Vaginal Birth delivery within 24 hours and C-section rate

Additional relevant MeSH terms:
Reproductive Control Agents
Physiological Effects of Drugs processed this record on June 23, 2017